Azithromycin in Periodontal Therapy: Beyond the Antibiotics

Dr. Vijendra Pal Singh, Dr. Sangeeta Umesh Nayak, Dr. Sunil Kumar Nettemu, Dr. Sowmya Nettem, Dr. Yen Hui Lee, Dr. Madhu B Verma

1Department of Periodontology and Implantology, Faculty of Dentistry, Melaka Manipal Medical College, Manipal Academy of Higher Education, Melaka, Malaysia; 2Department of Periodontology, Manipal College of Dental Sciences, Manipal Academy of Higher Education, Mangalore, India; 3Dental Clinic, Johor Baru, Malaysia; 4Private Practice, Lucknow, India.

ABSTRACT

Periodontitis is a multifactorial disease, in which microorganisms in plaque biofilm play a major role. Scaling and root planing is the primary mode of non-surgical treatment for periodontal disease. Adjunctive use of an antimicrobial is advocated in certain periodontal disease conditions. Azithromycin might be considered a promising adjunctive drug in the treatment for periodontal disease because of its distinguished characteristic of immunomodulation, anti-inflammatory and antibiotic property along with the accumulation in higher concentration into the acute reactant cells and sustained release at the site of infection. This antibiotic is popular for its very simple dosage regime and limited side effects. The objective of this literature review to highlight the mechanism and potential favourable role in the management of various form of the periodontal disease.

Keywords: Antibiotics; azithromycin; gingival overgrowth; macrolide; periodontal therapy.

INTRODUCTION

The complete elimination of tissue invasive microorganism is not possible with mere mechanical debridement in certain disease conditions. The systemic antimicrobials as an adjunctive mechanical therapy have been shown to enhance clinical benefits in these patients.1 Azithromycin (AZM) first synthesised in 1980, is a subclass of macrolides called azalides.2 AZM is an antibiotic used extensively for the treatment of a wide range of infections such as upper respiratory tract infections, middle ear infections, sexually transmitted infections and trachoma. It is also effective against the most common periodontopathogens: Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans), and Porphyromonas gingivalis (P. gingivalis). These invasive periodontal pathogens are difficult to eliminate by mechanical debridement alone, but the adjunctive use of systemic antibiotics can enhance the therapeutic response to non-surgical periodontal therapy (NSPT).1 AZM well plays a triple role in the treatment of moderate to advanced periodontitis. Its effectiveness against gram-negative bacteria, the ability to penetrate biofilm, and a long antibacterial half-life and short course make it an attractive antibiotic option as an adjunct to the management of advanced inflammatory periodontitis.3

Literature Search Methodology

An electronic search was conducted, for citations included till January 2017, to identify papers on azithromycin in periodontal therapy. Related studies and case reports written in the English language and published in major dental journals were included. Key words used for the search were the combination of “Azithromycin” and “Periodontal therapy” in surgical or non-surgical therapy.

Mechanism of Action

The mechanism of action of AZM is similar to other macrolide antibiotics.4 AZM thought to bind to donor site, prevents translocation of aminoacyl transfer RNA and inhibit the growing peptide chain from the acceptor site to the donor site, by competing for this site. This may cause premature termination of the peptide chain. AZM absorbs rapidly from gastrointestinal tract with bioavailability of about 40% and the peak plasma concentration is achieved 2-3 hours after the oral administration. The terminal half-life of AZM is 68 hours and average half-life is about 1-4 days.5

Dosage and Adverse Effects

The most common dosage regime for AZM (500 mg) orally once a day for three days, one hour before the food.6,7 However, the approved dosage of ZM in the United States
AZM was demonstrated to decrease the expression of proinflammatory cytokines [interleukin (IL)-1β, IL-6, IL-8 and tumour necrosis factor (TNF)-α], growth factors such as granulocyte-macrophage colony-stimulating factor and also increases the number of actively phagocytosing alveolar macrophages. Downregulation of the proinflammatory cytokines results into its anti-inflammatory property.

**Bacterial Resistance**
AZM has significantly less bacterial resistance to subgingival microflora of adult periodontitis compared to other commonly prescribed oral antibiotics. It was noticed that after 12 months the percentage of resistant species were reduced to levels approaching those detected before periodontal therapy.

**FAVOURABLE ROLE OF AZITHROMYCIN IN PERIODONTAL THERAPY**

**Bacteraemia Incidences**
The prevalence of scaling and root planing (SRP)-triggered bacteraemia in patients with periodontitis was reported 80.9% and it occurred more frequently immediately after treatment. AZM prophylaxis is beneficial in both reducing the bacteraemia incidence and the improvement of the effect of periodontal therapy.

**Effect on Biofilm**
In vivo, bacteria within the biofilm are thought to be protected from antibiotics. AZM demonstrated to reduce the formation of biofilm by interfering with the signals of quorum sensing. AZM permitting more effective antimicrobial activity against microbes within the biofilm by efficiently infiltrating this barrier. AZM is likely to be useful for the treatment of diseases caused by P. gingivalis biofilms.

**Accumulation in Gingival Crevicular Fluid (GCF)**
Drugs that enter the interstitial fluid seep through gingival connective tissue and eventually cross the junctional epithelium into the gingival crevice. However,
Table 2: Clinical studies used azithromycin as an adjunct to periodontal therapy.

| Author                  | Study design | Periodontal Status               | Sample size | Study duration | Treatment/AZM regimen | Outcomes                                                                 |
|-------------------------|--------------|----------------------------------|-------------|----------------|-----------------------|---------------------------------------------------------------------------|
| Smith et al (2002)      | RCT          | Chronic Periodontitis            | 44          | 22 weeks       | SRP+AZM-500 mg x 3 days / control-SRP+ Placebo | Significantly more reduction in pocket depth in AZM group, even with poor plaque control. |
| Mascarenhas et al (2005) | RCT          | Chronic Periodontitis in smoker   | 31          | 6 months       | SRP+ AZM 250 mg 1st day and one 250 mg for next 4 days. Control-SRP | Improved the efficacy of non-surgical periodontal therapy in smokers with moderate to advanced attachment loss. |
| Gomi et al (2007)       | Case-control | Severe chronic periodontitis     | 34          | 25 weeks       | SRP+ AZM 500 mg x 3 days. Control-SRP | Shortened the duration of periodontal treatment. |
| Dastoor et al (2007)    | RCT          | Chronic periodontitis, Heavy smoker | 30          | 6 months       | Surgical AZM-500 mg x 3 days. Control-Placebo | Sustained reduction in periodontal pathogens and rapid wound healing. No difference in clinical outcome. |
| Haas et al (2008)       | RCT          | Aggressive periodontitis         | 24          | 12 months      | SRP+AZM 500 mg x 3 days. Control-SRP+Placebo | Significantly more reduction in mean PPD. Potential to improve periodontal health |
| Pradeep et al (2008)    | RCT          | Chronic periodontitis            | 80          | 3 months       | SRF+0.5% AZM (controlled drug delivery system). Control-SRP | Enhanced the clinical result, and improved microbiological parameter. |
| Yashima et al (2009)    | Case-control | Chronic periodontitis            | 30          | 12 months      | AZM 500 mg x 3 days before SRP. FM-SRP (single visit), PM-SRP (3 visit over 7 days), Control: SRP (6 visit over 6 weeks) | Improvement in clinical parameters, with no significant differences between the two test groups. Different treatments for test and control groups make results difficult to compare. |
| Oteo et al (2010)       | RCT          | P. gingivalis associated Chronic periodontitis | 29          | 6 months       | SRP+ AZM 500 mg x3 days. Control-SRP | Significant improvement in clinical parameter and reduction in frequency of pathogenic microbes. |
| Sampaio et al (2011)    | RCT          | Chronic periodontitis            | 40          | 12 months      | SRF+AZM 500 mg x 5 days. Control-SRP | No adjunctive benefit. |
| Han et al (2012)        | RCT          | Chronic periodontitis            | 36          | 6 months       | SRF+ AZM 500 mg x 3 days. Control-SRP | Ineffective in lowering the subgingival level of important putative periodontal pathogens. |
| Haas et al (2012)       | RCT          | Aggressive periodontitis         | 24          | 12 months      | SRF+ AZM 500 mg x 3 days Control-SRP | No significant radiographic bone label change compared to placebo. |
| Pradeep et al 2013      | RCT          | Chronic periodontitis in smokers | 54          | 9 months       | SRF+0.5% AZM Control-SRP-placebo gel | Significant improvement in clinical outcome in the treatment of chronic periodontitis among smokers. |
| Ercan et al 2015        | RCT          | Aggressive periodontitis         | 45          | 3 months       | SRF+AZM, SRF+ Metronidazole +Amoxicilline, Control-SRP, | A non-significant improvement in periodontal parameter in the AZM and Metronidazole+ Amoxicilline groups. Good Healing tendency in the AZM group despite the baseline plaque scores. AZM might be active against the bacteria in dental biofilms. |
| Saleh et al 2016        | RCT          | Chronic periodontitis, Non-smoker | 37          | 3 months       | SRF+AZM, SRF+ Metronidazole +Amoxicilline, Control-SRP | Amoxicilline+ Metronidazole showed a higher reduction in PPD compared to AZM in the all sites analysis. |
| Latif et al 2016        | RCT          | Chronic periodontitis            | 40          | 90 days        | Group 1: SRF only, Group 2: SRP + AZM patch, Group 3: SRF + AZM tablet, Group 4: AZM buccal patch monotherapy, Group 5: AZM tablet 500 mg x 3 days monotherapy. | SRF + AZM tablets showed greater reduction in clinical parameters, however no significant gain in the clinical attachment was observed. |
| Martande et al 2016     | RCT          | A. actinomyctemataminas associated moderate to severe periodontitis | 70          | 12 months      | SRF+AZM (500 mg x 3 days), Control-SRP+Placebo | Significantly improved the clinical and microbiological parameters. |
A substantial amount of macrolide antibiotics may be taken up from interstitial fluid and concentrated inside macrolide reservoirs (fibroblasts, epithelial, inflammatory, and immune cells). They are thought to enhance macrolide distribution to gingiva and account for the large concentration difference between blood serum and gingival crevicular fluid (Table 1).

A study found AZM level in GCF, above the minimal inhibitory concentrations for the several periodontal pathogens after two weeks suggested, that AZM could produce beneficial antimicrobial and anti-inflammatory activity, even in patients who fail to complete the standard 1.5 g regimen.27

**Application in Local Drug Delivery**

Topical administration of AZM (0.5%) in systemically healthy chronic periodontitis patients demonstrated improvement in the clinical parameter as well as in subgingival microflora in both non-smokers and smokers. The authors hypothesised that the local application of AZM at the site of inflammation facilitated the penetration of the drug into the periodontal tissues, resulting in a high drug concentration and enhancing the bactericidal effect. The dual effect of the drug on the local microflora as well as on the invading pathogens may result in clinical improvement without systemic side effects or the development of bacterial resistance.

**Susceptibility to Periodontal Pathogens**

Various microorganisms including the A. actinomycetemcomitans, P. gingivalis, P. intermedia, and Pseudomonas aeruginosa are susceptible to AZM. This suggested that adjunctive AZM can potentially enhance the elimination of A. actinomycetemcomitans from patients with periodontitis especially under conditions in which neutrophils are greatly outnumbered by bacteria in gingival epithelial cells. A. actinomycetemcomitans has shown susceptibility to a low dose of AZM, which are resistant to high dosage of erythromycin, clarithromycin and roxithromycin. AZM is highly effective against P. gingivalis.

**Non-surgical Periodontal Therapy**

AZM has a wide spectrum of antibiotic action against periodontopathic bacteria as well as availability for a long duration, in periodontal lesions or in regions of surgical stress such as SRP may be an advantage for NSPT. The shift of bacterial flora from the elimination of the anaerobic environment to healthy state induce a tendency to heal, which is responsible for the improvement of inflammation and decrease in the periodontal pocket depth (PPD). The high concentration of AZM was maintained in inflamed tissues after uptake by phagocytic cells, which seems to make AZM ideal for the treatment of periodontitis.

Multiple randomised controlled trial (RCTs), conducted ranges from three to 12 months duration in chronic periodontitis patients including non-smokers and smokers investigated the effect of systemic AZM (500 mg x 3 days) in adjunct to SRP demonstrated the improvement in the efficacy of NSPT in reducing PPD and/or or improving attachment levels in chronic periodontitis (Table 1, 2).

However, contrary to these reports, few clinical studies found no additional benefit in the improvement of clinical parameters as well as a reduction in periodontal pathogens, with adjunctive use of AZM with SRP in chronic periodontitis patients in non-smoker and smoker.

Systemic antimicrobials have been advocated as a possible alternative to achieve better outcomes in the treatment of Aggressive periodontitis (AgP) in adjunct to SRP. The results from the clinical trials, demonstrate the improvements in periodontal clinical parameters at three months, and at 12 months as well as reduction in A. actinomycetemcomitans positive subjects. However one study found that AZM was ineffective in lowering the subgingival levels of putative periodontal pathogens in young AgP subjects, although periodontal health was achieved, another RCT also failed to show any change in radiographic bone level compared to placebo (Table 1, 2).

**Surgical Periodontal Treatment**

The only available RCT using the AZM adjunct to surgical periodontal therapy in heavy smokers showed rapid wound healing, short-term gingival inflammation and less plaque formation in AZM group, but failed to demonstrate any difference in PPD or clinical attachment with placebo. (Table 1, 2)

**Bone Regeneration**

In addition to the resolution of inflammation, remodelling and significant periodontal healing of the gingival tissues over time, regeneration of bone has been reported in few case reports in patients with severe localised and generalised periodontitis, following a single course of AZM. Bone formation was noted on periapical radiographs after the patients took two additional courses of AZM in the treatment of periodontal abscesses in conjunction with SRP. The results from these case reports raise the possibilities of bone formation with the use of AZM (Table 1).

**Drug Induced Gingival Overgrowth**

Clinically, AZM has been reported to be highly effective in treating Cyclosporin-A (CsA) induced gingival...
overgrowth. These results imply that AZM has an inhibitory effect on CsA induced gingival overgrowth (Table 1). Three possible mechanisms could be inferred, i) the inherent drug effect of AZM on gingival overgrowth might be related to its antibiotic activity, killing of oral bacteria, reducing local inflammation, and suppressing protein synthesis in fibroblasts; ii) AZM inhibits the inherent effects of CsA, The interaction between AZM and CsA is controversial, but no studies has been found to support this second mechanism; iii) AZM is associated with the inhibition of phagocytosis induced by CsA. Phagocytosis was thought to be the principal pathway of collagen degradation in CsA induced gingival overgrowth. Moreover, treatment with AZM appears to restore part of the phagocytosis mechanism.

REFERENCES

1. Haffajee AD, Socransky SS, Gunsolley JC. Systemic anti-infective periodontal therapy. A systematic review. Ann Periodontol. 2003;8:115-81.
2. Greenwood D. Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph. Oxford University Press; 2008. 429 p.
3. Hirsch R, Deng H, Laohachai MN. Azithromycin in periodontal treatment: More than an antibiotic. J Periodontal Res. 2012;47:137-48.
4. Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther. 2008;117:393-405.
5. Gomi K, Yashima A, Iino F, Kanazashi M, Nagano T, Shibukawa N, et al. Drug concentration in inflamed periodontal tissues after systemically administered azithromycin. J Periodontol. 2007;78:918-23.
6. Haffajee AD, Torresay G, Socransky SS. Clinical changes following four different periodontal therapies for the treatment of chronic periodontitis: 1-Year results. J Clin Periodontol. 2007;34:243-53.
7. Yashima A, Gomi K, Maeda N, Arai T. One-stage full-mouth versus partial-mouth scaling and root planing during the effective half-life of systemically administered azithromycin. J Periodontol. 2009;80:1406-13.
8. Han B, Emingil G, Özdemir G, Tervahartiala T, Vural C, Atilla G, et al. Azithromycin as an adjunctive treatment of generalized severe chronic periodontitis: clinical, microbiologic, and biochemical parameters. J Periodontol. 2012;83:1480-91.
9. Wildfeuer A, Laufen H, Leitold M, Zimmermann T. Comparison of the pharmacokinetics of three-day and five-day regimens of azithromycin in plasma and urine. J Antimicrob Chemother. 1993;31:51-6.
10. Beckey PN, Parra D, Colon A. Retrospective evaluation of a potential interaction between azithromycin and warfarin in patients stabilized on warfarin. Pharmacotherapy. 2000;20:1055-9.
11. Foster DR, Milan NL. Potential interaction between azithromycin and warfarin. Pharmacotherapy. 1999;19:902-8.
12. Herrera D, Roldán S, O’Connor A, Sanz M. The periodontal abscess (II). Short-term clinical and microbiological efficacy of 2 systemic antibacterial regimes. J Clin Periodontol. 2000;27:395-404.
13. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62, 993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother. 1989;33:277-82.
14. Bosnar M, Kelnerič Ž, Münić V, Eraković V, Parnham MJ. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol. 2002;450:277-89.
15. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med. 1991;91:5s-11s.
16. Uli Ö, Eraković V, Epelak I, Baršić K, Brjaška K, Ferendi E, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol. 2002;450:277-89.
17. Hodge S, Hodge G, Brozyńska S, Jersmann H, Holmes M, Reynolds PN. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J. 2006;28:846-55.
18. Van Winkelhoff AJ, Herrera D, Roldán S, O'Connor A, Sanz M. Antibiotic resistance in the subgingival microflora in patients with adult periodontitis. A comparative survey between Spain and the Netherlands. Ned Tijdschr Tandheelkd. 1999;106:290-4.
19. Haffajee AD, Patel M, Socransky SS. Microbiological changes associated with four different periodontal therapies for the treatment of chronic periodontitis. Oral Microbiol Immunol. 2008;23:148-57.
20. Lafaurie GI, Mayorga-Fayad I, Torres MF, Castillo DM, Aya MR, Barón A, et al. Periodontopathic microorganisms in periodontal disease regarded as biofilm infection: systemic administration of azithromycin. J Pharmacol Sci. 2010;113:126-33.
21. Maezono H, Noiri Y, Asahi Y, Yamaguchi M, Yamamoto R, Izutani N, et al. Antibiofilm effects of azithromycin and erythromycin on Porphyromonas gingivalis. Antimicrob Agents Chemother. 2011;55:5887-92.

SUMMARY

AZM represents a promising option for the adjunctive treatment of chronic inflammatory periodontal diseases, due to its various properties such as prolonged retention, good bioavailability, immunomodulation, accumulation in GCF, infiltrating the biofilm and marked penetration into both normal and pathological periodontal tissues. Evidence from the various studies supported the improvement in periodontal health with the adjunctive use of 500 mg AZM, in the NSPT. However, if future well-designed studies confirm these breakthrough findings, AZM could prove a valuable unique drug, not only as antibiotic but also as host modulating agent in the treatment of moderate to severe form of periodontitis and gingival overgrowth.
25. Gladue R, Snider M. Intracellular Accumulation of Azithromycin by Cultured Human Fibroblasts. Antimicrob Agents Chemother. 1990;34(10):56-60.

26. Lai DC, Ho W, Jain N, Walters JD. Azithromycin Concentrations in Blood and Gingival Crevicular Fluid After Systemic Administration. J Periodontol. 2011;82(12):1582-6.

27. Jain S, Lai DC, Walters JD. Effect of gingivitis on azithromycin concentrations in gingival crevicular fluid. J Periodontol. 2012;83(11):1222-8.

28. Pradeep AR, Sagar SV, Daisy H. Clinical and microbiologic effects of subgingivally delivered 0.5% azithromycin in the treatment of chronic periodontitis. J Periodontol. 2008;79(12):1355-61.

29. Pradeep AR, Rajap P, Agarwal E, Rao NS, Naik SB, Kalra N, et al. Local drug delivery of 0.5% azithromycin in the treatment of chronic periodontitis in smokers. Aust Dent J. 2013;58(3):34-40.

30. Lai DC, Schibler MR, Walters JD. Azithromycin Enhances Phagocytic Killing of Aggregatibacter actinomycetemcomitans Y4 by Human Neutrophils. J Periodontol. 2015;86(1):55-61.

31. Kitzis MD, Goldstein FW, Miegé M, Acer JF. In-vitro activity of azithromycin against various Gram-negative bacilli and anaerobic bacteria. J Antimicrob Chemother. 1990;25:15-8.

32. Pajukanta R. In vitro antimicrobial susceptibility of Porphyromonas gingivalis to azithromycin, a novel macrolide. Oral Microbiol Immunol. 1993;8:325-9.

33. Smith SR, Foyle DM, Daniels J, Joyost-Redhal S, Smales FC, Sefton A, et al. A double-blind placebo-controlled trial of azithromycin as an adjunct to nonsurgical treatment of periodontitis in adults: clinical results. J Clin Periodontol. 2002;29(5):44-6.

34. Gomi K, Yashima A, Nagano T, Kanzashi M, Maeda N, Arai T. Effects of full-mouth scaling and root planing in conjunction with systemically administered azithromycin. J Periodontol. 2007;78:422-9.

35. Saleh A, Rincon J, Tan A, Firth M. Comparison of adjunctive azithromycin and amoxicillin/metronidazole for patients with chronic periodontitis: preliminary randomized controlled trial. Aust Dent J. 2016;61:469-81.

36. Latif SA, Vandana KL, Thimmashetty J, Dalvi PJ. Azithromycin buccal patch in treatment of chronic periodontitis. Indian J Pharmaco. 2016;48:208-13.

37. Fonseca DC, Cortelli JR, Cortelli SC, Miranda Cota LO, Machado Costa LC, Moreira Castro MV, et al. Clinical and Microbiological Evaluation of Scaling and Root Planing per Quadrant and One-Stage Full Mouth Disinfection Associated With Azithromycin or Chlorhexidine: A Clinical Randomized Controlled Trial. J Periodontol. 2015;86(1):1340-51.

38. Otoe A, Herrera D, Figuero E, O’Connor A, González I, Sanz M. Azithromycin as an adjunct to scaling and root planing in the treatment of Porphyromonas gingivalis-associated periodontitis: A pilot study. J Clin Periodontol. 2017;43(7):1005-15.

39. Mascaréñas P, Gapski R, Al-Shammari K, Hill R, Soehren S, Fenn JC, et al. Clinical response of azithromycin as an adjunct to nonsurgical periodontal therapy in smokers. J Periodontol. 2005;76:426-36.

40. Sampaio E, Rocha M, Figueiredo LC, Faveri M, Duarte PM, Gomes Lira EA, et al. Clinical and microbiological effects of azithromycin in the treatment of generalized chronic periodontitis: A randomized placebo-controlled clinical trial. J Clin Periodontol. 2011;38:838-46.

41. Erkan E, Uzun BC, Ustaoglu G. Effects of azithromycin versus metronidazole – amoxicillin combination as an adjunct to nonsurgical periodontal therapy of generalized aggressive periodontitis. Niger J Clin Pract. 2013;18:506-10.

42. Haas AN, De Castro GD, Moreno T, Susin C, Albandar JM, Oppermann RV, et al. Azithromycin as an adjunct to aggressive periodontitis: 12-Months randomised clinical trial. J Clin Periodontol. 2008;35:906-704.

43. Martande SS, Pradeep AR, Singh SF, Kamwari M, Naik SR, Suke DK, et al. Clinical and microbiological effects of systemically administered azithromycin in aggressive periodontitis: Radiographic findings of a 12-month randomized clinical trial. J Periodontol. 2016;48:208-13.

44. Haas AN, Silva-Boghossian CM, Colombo AP, Susin C, Albandar JM, Oppermann RV, et al. Adjunctive azithromycin in the treatment of aggressive periodontitis: Microbiological findings of a 12-month randomized clinical trial. J Dent. 2012;40:536-63.

45. Haas AN, Selemel F, Segatto P, Susin C, Albandar JM, Oppermann RV, et al. Azithromycin as an adjunct to non-surgical periodontal therapy of Aggregatibacter actinomycetemcomitans associated periodontitis: a randomized placebo-controlled clinical trial. J Investig Clin Dent. 2016;7:62-80.

46. Haas AN, Silva-Boghossian CM, Colombo AP, Susin C, Albandar JM, Oppermann RV, et al. Adjunctive azithromycin in the treatment of aggressive periodontitis: Radiographic findings of a 12-month randomized clinical trial. J Dent. 2012;40:536-63.

47. Dastoor SF, Travas S, Neiva RF, Rayburn LA, Giannobile WV, Wang HL. Effect of Adjunctive Systemic Azithromycin With Periodontal Surgery in the Treatment of Chronic Periodontitis in Smokers: A Pilot Study. J Periodontol. 2007;78:1887-96.

48. Hirsch R. Periodontal healing and bone regeneration in response to azithromycin. Aust Dent J. 2010;55:193-9.

49. Fujise O, Miura M, Hamachi T, Aida Y, Nishimura F. Regenerative effect of azithromycin on periodontitis with different levels of gingival inflammation: Three case reports. Aust Dent J. 2014;59:245-51.

50. Schmidt EF, Brett WA. Benefits of additional courses of systemic azithromycin in periodontal disease case report. N Y State Dent J. 2007;73:40-5.

51. Wirsberger GH, Pfragner R, Mauric A, Zach B, Bogiatzis A, Holzer H. Effect of antibiotic treatment with azithromycin on cyclosporine A-induced gingival hyperplasia among renal transplant recipients. Transplant Proc. 1998;30:2117-9.

52. Citterio F, Di Pinto A, Borzi MT, Scatà MC, Foco M, Pozzetto I, et al. Azithromycin treatment of gingival hyperplasia in kidney transplant recipients is effective and safe. Transplant Proc. 2001;33:2314-5.

53. Ljutić D, Rumboldt Z. Possible interaction between azithromycin and cyclosporin: a case report. Nephron. 1995;70:130.

54. Paik J, Kim CS, Cho KS, Choi JK, Kim CK, Choi SH. Inhibition of cyclosporin A-induced gingival overgrowth by azithromycin through phagocytosis: an in vivo and in vitro study. J Periodontol. 2004;75:380-7.